The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals.
“Our agreement with Lilly will enable us to bring Bigfoot’s insulin delivery innovations to the millions of people who trust and rely on Lilly’s insulin products,” co-founder & CEO Jeffrey Brewer said in prepared remarks. “We are thrilled to partner with Lilly in our efforts to innovate for people with diabetes and their care teams.”
Bigfoot is developing a closed-loop automated insulin delivery system and a connected insulin pen – both of which the company plans to offer as monthly subscriptions.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.